Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome



Status:Completed
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 65
Updated:7/13/2016
Start Date:July 2015
End Date:June 2016

Use our guide to learn which trials are right for you!

A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome

This study will evaluate the effect of oral eleclazine (GS-6615) on QTc interval, safety,
and tolerability in adults with long QT2 syndrome.


Inclusion Criteria:

- Individuals with an established diagnosis of LQT2 (by genotype testing)

- Mean (of triplicate) QTc interval ≥ 480 msec for at least four out of seven time
points, determined by standard 12-lead ECG, at screening

Exclusion Criteria:

- Known mutations associated with LQT1 or LQT3

- Known or suspected history of seizures or epilepsy

- History of heart failure defined as New York Heart Association (NYHA) Class IV and/or
known left ventricular ejection fraction (EF) ≤ 45%

- Body mass index (BMI) ≥ 36 kg/m^2 at screening

- Severe renal impairment at screening (defined as an estimated glomerular filtration
rate (eGFR) < 30 mL/min/1.73m^2, using the 4 Variable Modification of Diet in Renal
Disease (MDRD) equation), as determined by the study center

- Abnormal liver function tests at screening, defined as alanine aminotransferase (ALT)
or aspartate aminotransferase (AST) > 2 x upper limit of normal (ULN), or total
bilirubin > 1.5 x ULN

- An aborted cardiac arrest (ACA), implantable cardioverter-defibrillator (ICD)
implantation, syncopal episode, or appropriate ICD therapy within 3 months prior to
screening

- Any other condition or circumstance that in the opinion of the investigator would
preclude compliance with the study protocol
We found this trial at
1
site
?
mi
from
Rochester, NY
Click here to add this to my saved trials